Latest Financial Position News

Beacon Minerals produced 5,419 ounces of gold in Q1 2026 amid operational shifts at Jaurdi, completed key asset sales to Forrestania, and set a June quarter production target of 5,000 to 6,000 ounces.

Aurum Resources has confirmed a significant 220m depth extension of gold mineralisation at its Boundiali Gold Project in Côte d'Ivoire, reinforcing its 3.03Moz resource and setting the stage for upcoming feasibility studies.

88 Energy has bolstered its Alaska North Slope exploration with a substantial prospective resource update, fresh seismic data acquisitions, and a heavily oversubscribed A$5 million equity placement, setting the stage for its Augusta-1 well spud in early 2027.

Castle Minerals has consolidated a dominant 184 km² landholding in Western Australia’s Murchison Gold District and advanced Côte d’Ivoire exploration toward drill-ready targets, supported by strategic leadership appointments.

Netwealth delivered a resilient March quarter with $4 billion in net inflows, pushing total funds under administration to $125.8 billion despite a 3.7% market dip. Growth in Managed Accounts and new intermediary relationships underpin ongoing momentum.

Many Peaks Minerals has completed more than 10,150m of drilling in the March quarter, delivering strong gold intercepts at its Ferké Gold Project in Côte d’Ivoire that underpin an upcoming maiden resource estimate and pre-feasibility study.

Genesis Minerals posted robust March quarter results with 67,497oz gold production and a cash pile nearing A$600 million, while accelerating development at Tower Hill and preparing to close a transformative A$639 million acquisition of Magnetic Resources.

Noronex completed maiden drilling programs at key uranium and copper projects while bolstering its cash position through strategic asset sales. The company also formalised a 51% stake in its Etango North uranium project and navigates a CEO transition.

Wildcat Resources (ASX: WC8) has expanded its Bolt Cutter Central lithium discovery footprint beyond 2.3km with multiple high-grade spodumene intercepts, while advancing the Definitive Feasibility Study for its Tabba Tabba Project. The company maintains a strong cash position of A$43.3 million as it prepares for further drilling and development milestones.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Westar Resources is pressing forward with its Mageye anomaly exploration in WA's Murchison region while negotiating heritage agreements and managing a $1.15 million cash balance. The company also secured new tenements in the Northern Territory and awaits shareholder approval for a $1.49 million capital raise.

Comvita launches a NZ$30 million renounceable Rights Offer to refinance debt and bring Southeast Asian consumer giant Fraser and Neave onboard as a strategic investor with a near 20% stake.